XT
NKTR icon

XTX Topco’s Nektar Therapeutics NKTR Stock Holding History

XTX Topco’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Buy
19,125
+15,022
+366% +$1.1M 0.02% 1512
2026
Q1 		$295K Sell
4,103
-3,093
-43% -$176K 0.01% 2492
2025
Q4 		$304K Buy
7,196
+1,299
+22% +$72.7K 0.01% 2050
2025
Q3 		$336K Buy
+5,897
New +$195K 0.02% 1422
2025
Q2 		– Sell
-3,828
Closed -$39K – 2904
2025
Q1 		$39K Sell
3,828
-12,485
-77% -$163K ﹤0.01% 2032
2024
Q4 		$228K Buy
16,313
+13,968
+596% +$246K 0.02% 1452
2024
Q3 		$45.7K Buy
+2,345
New +$44.7K ﹤0.01% 1705
2024
Q1 		– Sell
-4,881
Closed -$41.4K – 2157
2023
Q4 		$41.4K Buy
+4,881
New +$37K 0.01% 1263
2023
Q3 		– Sell
-788
Closed -$6.8K – 1859
2023
Q2 		$6.8K Buy
+788
New +$8.4K ﹤0.01% 1350
2023
Q1 		– Sell
-10,910
Closed -$370K – 1534
2022
Q4 		$370K Buy
10,910
+8,284
+315% +$401K 0.08% 446
2022
Q3 		$126K Buy
2,626
+615
+31% +$36.6K 0.03% 899
2022
Q2 		$115K Sell
2,011
-254
-11% -$16K 0.05% 611
2022
Q1 		$183K Buy
+2,265
New +$335K 0.08% 429

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

XTX Topco's NKTR Position: Q2 2026 in Review

XTX Topco increased its Nektar Therapeutics (NKTR) stake by 366% in Q2 2026, buying an estimated $1.1M and bringing the position to 19,125 shares worth $1.34M. The position accounts for 0.02% of the portfolio, ranked #1512.

XTX Topco first reported a position in NKTR in Q1 2022 and has held it in 13 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • XTX Topco held 19,125 shares of Nektar Therapeutics worth $1.34M as of Q2 2026.
  • XTX Topco bought 15,022 Nektar Therapeutics shares in Q2 2026, an estimated $1.1M.
  • Nektar Therapeutics made up 0.02% of XTX Topco's portfolio in Q2 2026, its #1512 holding.
  • XTX Topco first reported a position in Nektar Therapeutics in Q1 2022 and has held it in 13 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on XTX Topco's 13F filing for Q2 2026, filed 14 Aug 2026.